UA89545C2 - Способ лечения или предупреждения состояний, вызванных грамположительными бактериями - Google Patents
Способ лечения или предупреждения состояний, вызванных грамположительными бактериями Download PDFInfo
- Publication number
- UA89545C2 UA89545C2 UAA200801080A UAA200801080A UA89545C2 UA 89545 C2 UA89545 C2 UA 89545C2 UA A200801080 A UAA200801080 A UA A200801080A UA A200801080 A UAA200801080 A UA A200801080A UA 89545 C2 UA89545 C2 UA 89545C2
- Authority
- UA
- Ukraine
- Prior art keywords
- bile acid
- indicated
- gram
- neutral lipid
- positive bacteria
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 15
- 241000192125 Firmicutes Species 0.000 title claims abstract description 14
- 230000002265 prevention Effects 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title claims description 19
- 150000002632 lipids Chemical class 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 47
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 42
- 230000007935 neutral effect Effects 0.000 claims abstract description 39
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 39
- 239000003613 bile acid Substances 0.000 claims abstract description 26
- 208000015181 infectious disease Diseases 0.000 claims abstract description 11
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims abstract description 10
- 230000004768 organ dysfunction Effects 0.000 claims abstract description 9
- 206010053159 Organ failure Diseases 0.000 claims abstract description 5
- 206010040047 Sepsis Diseases 0.000 claims abstract description 5
- 206010040070 Septic Shock Diseases 0.000 claims abstract description 5
- 230000036303 septic shock Effects 0.000 claims abstract description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 18
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 16
- 239000000839 emulsion Substances 0.000 claims description 11
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical group C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 claims description 8
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical group [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 229940099352 cholate Drugs 0.000 claims 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical group C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 abstract description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 36
- 235000012000 cholesterol Nutrition 0.000 description 18
- -1 phosphatidylcholine Chemical class 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 108010083590 Apoproteins Proteins 0.000 description 7
- 102000006410 Apoproteins Human genes 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 150000001840 cholesterol esters Chemical class 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 108010071619 Apolipoproteins Proteins 0.000 description 4
- 102000007592 Apolipoproteins Human genes 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000001830 cholanoic acids Chemical class 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 2
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002812 cholic acid derivative Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015961 delipidation Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- WDFRNBJHDMUMBL-OICFXQLMSA-M sodium;(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 WDFRNBJHDMUMBL-OICFXQLMSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Описано лечение, предупреждение и профилактика состояний, таких как-то сепсис, септический шок, синдром системного воспалительного ответа (ССВО), ССВО с дисфункцией или недостаточностью органа, недостаточностью органа и дисфункцией органа. Представленные состояния ассоциированы с инфекцией грамположительными бактериями. Лечение состоит в применении композиции, которая содержит фосфолипид, нейтральный липид и желчную кислоту или соль желчной кислоты.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71207505P | 2005-08-29 | 2005-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA89545C2 true UA89545C2 (ru) | 2010-02-10 |
Family
ID=37809418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200801080A UA89545C2 (ru) | 2005-08-29 | 2006-08-25 | Способ лечения или предупреждения состояний, вызванных грамположительными бактериями |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070049554A1 (ru) |
EP (1) | EP1933856A4 (ru) |
JP (1) | JP5432525B2 (ru) |
KR (1) | KR101413361B1 (ru) |
CN (1) | CN101252942B (ru) |
AP (1) | AP2626A (ru) |
AU (1) | AU2006284990B2 (ru) |
BR (1) | BRPI0615411A2 (ru) |
CA (1) | CA2621066C (ru) |
HK (1) | HK1115325A1 (ru) |
NO (1) | NO20080637L (ru) |
NZ (1) | NZ565590A (ru) |
RU (1) | RU2391985C2 (ru) |
UA (1) | UA89545C2 (ru) |
WO (1) | WO2007027636A2 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011022707A1 (en) * | 2009-08-21 | 2011-02-24 | Henk-Andre Kroon | Vesicular formulations |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
US9023833B2 (en) | 2012-12-18 | 2015-05-05 | Sepsicure, LLC | Method for treating sepsis in patients with albumin, cholesterol and HDL levels above minimum thresholds |
US20160038454A1 (en) * | 2013-03-15 | 2016-02-11 | Pharmagenesis, Inc. | Intravenous formulations of triptolide compounds as immunomodulators and anticancer agents |
EP2805612A1 (en) | 2013-05-22 | 2014-11-26 | University of Graz | Lysophospholipids against American Foulbrood |
HRP20211669T1 (hr) | 2015-06-30 | 2022-02-18 | Sequessome Technology Holdings Limited | Multifazni pripravci |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2220331A (en) * | 1936-02-28 | 1940-11-05 | Schering Corp | Remedy for infection by cocci and process of manufacturing it |
US4072575A (en) * | 1976-05-03 | 1978-02-07 | Mcdonnell Douglas Corporation | Broth and method for detecting E. coli in mixed water samples |
US4340671A (en) * | 1977-08-29 | 1982-07-20 | Mcdonnell Douglas Corporation | E. coli sensitivity broth |
JPS61172826A (ja) * | 1985-01-25 | 1986-08-04 | Tanabe Seiyaku Co Ltd | 魚類連鎖球菌症の予防・治療用組成物 |
JPS6259214A (ja) * | 1985-09-09 | 1987-03-14 | Kyowa Yakuhin Kk | 水生動物感染症起因菌の抗菌剤 |
NO178843C (no) * | 1988-07-11 | 1996-06-19 | Sspl Sa Safe Sex Prod Licens | Fremgangsmåte for fremstilling av et farmasöytisk preparat for å forhindre seksuelt overförbare sykdommer |
JPH0672882A (ja) * | 1991-07-29 | 1994-03-15 | Sennosuke Tokumaru | インターフェロン−β産生増強剤 |
US6306621B1 (en) * | 1991-11-18 | 2001-10-23 | The United States Of America As Represented By The Administrator Of The U.S. Environmental Protection Agency | Membrane filter agar medium for simultaneous detection of total coliforms and E. coli |
US5587366A (en) * | 1992-08-12 | 1996-12-24 | The Rogosin Institute | Compositions useful in prophylaxis and therapy of endotoxin related conditions |
US5674855A (en) * | 1992-08-12 | 1997-10-07 | The Rogosin Institute | Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions |
US5344822A (en) * | 1992-08-12 | 1994-09-06 | The Rogosin Institute | Methods useful in endotoxin prophylaxis and therapy |
JPH07277986A (ja) * | 1994-04-08 | 1995-10-24 | Kazuo Hosoya | 胆汁酸塩を主成分とするメチシリン耐性黄色ブドウ球菌用抗菌 剤成分 |
US5932536A (en) * | 1994-06-14 | 1999-08-03 | The Rockefeller University | Compositions for neutralization of lipopolysaccharides |
JPH1017476A (ja) * | 1996-06-28 | 1998-01-20 | Nippon Seiyaku Kk | 敗血症用非経口製剤及びそれによる予防及び治療方法 |
US6165997A (en) * | 1997-11-20 | 2000-12-26 | Statens Serum Institut | Phospholipids having antimicrobial activity with or without the presence of antimicrobials |
US9040078B2 (en) * | 2000-01-10 | 2015-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases of the nervous system |
US7811999B2 (en) * | 2000-01-10 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Use of lipid conjugates in the treatment of diseases |
CU22789A1 (es) * | 2000-06-29 | 2002-07-24 | Ct Nac Biopreparados | Mezcla nutritiva y procedimiento para la identificación y recuento temprano de organismos gram-negativos |
PL213982B1 (pl) * | 2001-07-27 | 2013-05-31 | Nutricia Nv | Zastosowanie fosfolipidów, triglicerydów i cholesterolu oraz kompozycja do podawania dojelitowego |
US20030032674A1 (en) * | 2001-08-13 | 2003-02-13 | Hwang Daniel H. | Use of unsaturated fatty acids to treat severe inflammatory diseases |
US20030143658A1 (en) * | 2002-01-28 | 2003-07-31 | Casella Linda J. Richardson | Rapid methods and devices for the detection of coliform and the detection and confirmation of E. coil |
US20080318870A1 (en) * | 2007-06-19 | 2008-12-25 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
-
2006
- 2006-08-25 AU AU2006284990A patent/AU2006284990B2/en not_active Ceased
- 2006-08-25 NZ NZ565590A patent/NZ565590A/en not_active IP Right Cessation
- 2006-08-25 US US11/510,094 patent/US20070049554A1/en not_active Abandoned
- 2006-08-25 WO PCT/US2006/033581 patent/WO2007027636A2/en active Application Filing
- 2006-08-25 KR KR1020087005056A patent/KR101413361B1/ko active IP Right Grant
- 2006-08-25 RU RU2008111897/14A patent/RU2391985C2/ru not_active IP Right Cessation
- 2006-08-25 UA UAA200801080A patent/UA89545C2/ru unknown
- 2006-08-25 CA CA2621066A patent/CA2621066C/en active Active
- 2006-08-25 AP AP2008004344A patent/AP2626A/xx active
- 2006-08-25 JP JP2008529172A patent/JP5432525B2/ja not_active Expired - Fee Related
- 2006-08-25 CN CN200680031406XA patent/CN101252942B/zh not_active Expired - Fee Related
- 2006-08-25 BR BRPI0615411-5A patent/BRPI0615411A2/pt not_active Application Discontinuation
- 2006-08-25 EP EP06813861A patent/EP1933856A4/en not_active Ceased
-
2008
- 2008-02-05 NO NO20080637A patent/NO20080637L/no not_active Application Discontinuation
- 2008-10-08 HK HK08111119.5A patent/HK1115325A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP5432525B2 (ja) | 2014-03-05 |
CN101252942B (zh) | 2010-12-22 |
AU2006284990A1 (en) | 2007-03-08 |
CN101252942A (zh) | 2008-08-27 |
KR20080066914A (ko) | 2008-07-17 |
AP2626A (en) | 2013-03-26 |
WO2007027636A2 (en) | 2007-03-08 |
CA2621066A1 (en) | 2007-03-08 |
US20070049554A1 (en) | 2007-03-01 |
EP1933856A4 (en) | 2008-11-19 |
CA2621066C (en) | 2011-11-29 |
EP1933856A2 (en) | 2008-06-25 |
HK1115325A1 (en) | 2008-11-28 |
AU2006284990B2 (en) | 2011-01-06 |
RU2391985C2 (ru) | 2010-06-20 |
KR101413361B1 (ko) | 2014-06-27 |
BRPI0615411A2 (pt) | 2012-12-04 |
WO2007027636A3 (en) | 2007-09-07 |
RU2008111897A (ru) | 2009-10-10 |
JP2009506120A (ja) | 2009-02-12 |
NO20080637L (no) | 2008-03-26 |
NZ565590A (en) | 2010-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5614507A (en) | Protein and peptide free, neutral lipid and phospholipid containing compositions useful in treating endotoxemia | |
US20080275007A1 (en) | Charged phospholipid compositions and methods for their use | |
RU2174839C2 (ru) | Фармацевтическая композиция, не содержащая белков и пептидов, способ лечения людей или животных, страдающих от эндотоксемии, и способ профилактики заболевания | |
UA89545C2 (ru) | Способ лечения или предупреждения состояний, вызванных грамположительными бактериями | |
CN111278441A (zh) | 用于治疗纤维化的组合物和方法 | |
US5587366A (en) | Compositions useful in prophylaxis and therapy of endotoxin related conditions | |
RU2248796C2 (ru) | Фармацевтическая композиция (варианты), не содержащая белков и пептидов, для нейтрализации и/или удаления эндотоксинов из организма | |
MXPA97000929A (en) | Use and useful compositions in the prophylaxis and therapy of conditions related to endotox |